CytomX Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de CytomX Therapeutics' es Sean McCarthy , nombrado en Aug 2011, tiene una permanencia de 12.67 años. compensación anual total es $2.61M, compuesta por 25% salario y 75% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.78% de las acciones de la empresa, por valor de $884.94K. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 4.3 años, respectivamente.
Información clave
Sean McCarthy
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 25.0% |
| Permanencia del CEO | 12.7yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?
Feb 02
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?
Dec 29Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Dec 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Compensación vs. Mercado: La compensación total de Sean($USD2.61M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Sean ha sido consistente con los resultados de la empresa en el último año.
CEO
Sean McCarthy (56 yo)
12.7yrs
Permanencia
US$2,611,138
Compensación
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 12.7yrs | US$2.61m | 0.78% $ 842.6k | |
| Senior VP & Chief Scientific Officer | 1.3yrs | US$1.21m | 0.088% $ 94.5k | |
| Senior VP | 3yrs | US$1.05m | 0.078% $ 84.2k | |
| Senior VP of Finance & Accounting | 2.7yrs | sin datos | 0.037% $ 40.4k | |
| Senior VP | 5.9yrs | US$1.21m | 0.096% $ 103.1k | |
| Senior VP & Chief Human Resources Officer | no data | sin datos | sin datos | |
| Senior Vice President of Intellectual Property | 5.2yrs | sin datos | sin datos | |
| Senior VP & Chief Medical Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Quality & Product Manufacturing | 1.3yrs | sin datos | sin datos | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | sin datos |
3.0yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CTMX se considera experimentado (3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 12.7yrs | US$2.61m | 0.78% $ 842.6k | |
| Independent Director | 4.9yrs | US$75.12k | 0.0076% $ 8.2k | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.3yrs | US$76.98k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$77.69k | 0% $ 0 | |
| Lead Independent Director | 8.6yrs | US$106.49k | 0% $ 0 | |
| Independent Director | 4yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.3yrs | US$8.03m | sin datos | |
| Independent Director | 2.6yrs | US$68.89k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.3yrs | sin datos | sin datos |
4.3yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: La junta directiva de CTMX se considera experimentada (4.3 años de antigüedad promedio).